Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Merck Announces First-Quarter 2026 Dividend
11:30am, Tuesday, 18'th Nov 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2026 Dividend.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF.
Merck Has Many Bullish Attributes (Technical Analysis)
04:18am, Tuesday, 18'th Nov 2025
Merck presents a bullish investment case with strong valuation, improving grades, and a well-supported, growing dividend. MRK's technical setup is positive: price trades above its 30-week EMA, momentu
Merck & Co., Inc. (NYSE:MRK) Receives $104.50 Average PT from Brokerages
02:34am, Tuesday, 18'th Nov 2025
Shares of Merck and Co., Inc. (NYSE: MRK - Get Free Report) have received a consensus rating of "Hold" from the eighteen brokerages that are presently covering the stock, Marketbeat.com reports. One a
Merck & Co., Inc. (MRK) M&A Call Transcript
10:27am, Monday, 17'th Nov 2025
Merck & Co., Inc. ( MRK ) M&A Call November 17, 2025 8:00 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Dean Li - Executi
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
09:36am, Monday, 17'th Nov 2025
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
09:07am, Monday, 17'th Nov 2025
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
08:34am, Monday, 17'th Nov 2025
Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug.
Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November
04:31am, Monday, 17'th Nov 2025
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Dividend growth picked up from companies in the first hal
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
06:17pm, Friday, 14'th Nov 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Market Today: Data Delays, CEO Shifts, M&A and Deals
05:35pm, Friday, 14'th Nov 2025
Guru Stock PicksSteven Cohen has made the following transactions:Reduce in FLR by 57.92%Sold out in TATTAdd in GDEN by 26.14%New position in KEXValueAct Capital
Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium Transcript
05:01pm, Friday, 14'th Nov 2025
Merck & Co., Inc. ( MRK ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michelle Kehily Conference Call Participants Elena Meng Michael Paas Stephen S. Morse Magd
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
03:19pm, Friday, 14'th Nov 2025
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
11:20am, Friday, 14'th Nov 2025
Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.
